Reference News website reported on June 16, citing a report from Singapore's Lianhe Zaobao website on June 16 that Chinese biotech stocks have shaken off a four-year slump and become one of the best-performing sectors in Asia this year, with funds看好 its further upside potential.
According to a report by Bloomberg News on June 15, the Hang Seng Biotechnology Index has risen more than 60% this year, thanks to investor enthusiasm sparked by two multibillion-dollar deals involving China's innovative drugs being licensed to multinational pharmaceutical companies. The upward momentum of two highly anticipated domestic drugmakers after their listings has further enhanced the attractiveness of the sector.
Yiqi Liu, a senior investment analyst at Exosome Capital Management in New York, said: "Chinese biotech is no longer just an emerging story. Unlike 10 years ago, it is now becoming a disruptive force reshaping the global landscape of drug innovation. It has a solid scientific foundation, clear economic logic, and its R&D pipeline is beginning to yield results."
The surge in listed Chinese biotech companies further demonstrates that mainland China is gradually becoming a global innovation hub. This year, the gains in this sector have already outpaced China's tech stocks, which were mainly driven by breakthroughs in artificial intelligence models released in January by DeepSeek.
It was reported that Pfizer announced on May 19 that it would pay $1.25 billion upfront to obtain the license for an anti-cancer drug from Sanofi Pharmaceuticals in China.
Two weeks later, Bristol Myers Squibb said it would pay up to $11.5 billion to acquire the license for an anti-cancer drug from German BioNTech. This drug was originally licensed to BioNTech by China-based Pumai Biopharmaceuticals in 2023.
The report noted that China's increasing influence through mergers and acquisitions in the pharmaceutical sector has also drawn investor attention. In just the first quarter of this year, transactions involving Chinese companies reached $36.9 billion, accounting for more than half of the global total of $67.5 billion.
Dong Chen, chief strategist for Asia at Pictet Wealth Management, said that China's biotech companies are experiencing their "own DeepSeek moment," with more room for future growth.
On February 20, 2025, research staff at Zhongke Baik (Tianjin) Biopharmaceutical Co., Ltd., located in Binhai-Zhongguancun Science City in Beijing-Tianjin-Hebei region, compare experimental data in the laboratory (Xinhua).
Original article: https://www.toutiao.com/article/7516400234621076008/
Disclaimer: The article represents the views of the author. Please express your attitude by clicking the 【Like/Dislike】buttons below.